Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Applied Therapeutics Inc before investing.

In this article, we go over a few key elements for understanding Applied Therapeutics Inc’s stock price such as:

• Applied Therapeutics Inc’s current stock price and volume
• Why Applied Therapeutics Inc’s stock price changed recently
• Upgrades and downgrades for APLT from analysts
• APLT’s stock price momentum as measured by its relative strength

About Applied Therapeutics Inc (APLT)

Before we jump into Applied Therapeutics Inc’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

Applied Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is focused on developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need. The Company’s lead drug candidate, govorestat, is a novel central nervous system penetrant Aldose Reductase Inhibitor (ARI) for the treatment of central nervous system (CNS) rare metabolic diseases, including Galactosemia, Sorbitol Dehydrogenase (SORD) Deficiency, and PMM2-CDG. The Company is also developing AT-001, a novel potent ARI, for the treatment of Diabetic Cardiomyopathy (DbCM) a fatal fibrosis of the heart. It has completed a Phase I/II clinical trial evaluating AT-001 in approximately 120 patients with type 2 diabetes, in which no drug-related adverse effects or tolerability issues were observed. The preclinical pipeline also includes AT-003, an ARI designed to cross through the back of the eye when dosed orally, for the treatment of Diabetic retinopathy.

Want to learn more about Applied Therapeutics Inc’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Applied Therapeutics Inc.

Applied Therapeutics Inc’s Stock Price as of Market Close

As of April 04, 2024, 4:00 PM, CST, Applied Therapeutics Inc’s stock price was $5.92.

Applied Therapeutics Inc is down 4.67% from its previous closing price of $6.21.

During the last market session, Applied Therapeutics Inc’s stock traded between $6.08 and $6.39. Currently, there are 84.24 million shares of Applied Therapeutics Inc stock available for purchase.

Unfortunately, Applied Therapeutics Inc’s P/E ratio is not significant enough to use for stock price evaluation. We recommend investors evaluate other financial metrics to understand its overall valuation.

Applied Therapeutics Inc Stock Price History

Applied Therapeutics Inc’s (APLT) price is currently down 12.94% so far this month.

During the month of April, Applied Therapeutics Inc’s stock price has reached a high of $6.70 and a low of $5.85.

Over the last year, Applied Therapeutics Inc has hit prices as high as $9.39 and as low as $0.76. Year to date, Applied Therapeutics Inc’s stock is up 678.95%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Applied Therapeutics Inc Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of April 03, 2024, there was 1 analyst who downgraded Applied Therapeutics Inc’s stock and 0 analysts who upgraded over the last month.

Additionally, you'll want to evaluate Applied Therapeutics Inc’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Applied Therapeutics Inc’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Applied Therapeutics Inc (APLT) by visiting AAII Stock Evaluator.

Relative Price Strength of Applied Therapeutics Inc

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of April 03, 2024, Applied Therapeutics Inc has a weighted four-quarter relative price strength of 58.19%, which translates to a Momentum Score of 98 and is considered to be Very Strong.

Want to learn more about how Applied Therapeutics Inc is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Applied Therapeutics Inc Stock Price: Bottom Line

As of April 4, 2024, Applied Therapeutics Inc’s stock price is $5.92, which is down 4.67% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Applied Therapeutics Inc stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.